PLUS1
4.10
0.01 (0.24%)
0.01 (0.24%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Amneal Pharmaceuticals Inc | AMRX | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.01 | 0.24% | 4.10 | 19:40:18 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.14 | 4.01 | 4.169 | 4.10 | 4.09 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,402 | 1,869,391 | $ 4.08 | $ 7,618,787 | 1,308,909 | 2.40 - 5.79 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:00:00 | 81,503 | $ 4.10 | USD |
Amneal Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 605.28M | 147.63M | 145.53M | $ 1.63B | $ 26.35M | -2.71 | 8.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Amneal Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/11/2020 | 08:35 | Business Wire | Amneal Receives Abbreviated New Drug Application Approval.. |
| 11/06/2020 | 16:23 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/06/2020 | 06:00 | Business Wire | Amneal Reports Third Quarter 2020 Financial Results |
| 10/15/2020 | 08:00 | Business Wire | Amneal to Report Third Quarter 2020 Results on November 6,.. |
| 10/08/2020 | 15:10 | Business Wire | Company Profile for Amneal Pharmaceuticals |
| 10/08/2020 | 08:00 | Business Wire | Amneal & PL Developments Launch Store Brand Program of.. |
| 9/01/2020 | 08:00 | Business Wire | Amneal to Virtually Participate at the Morgan Stanley Global.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AMRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.06 | 4.385 | 4.01 | 4.16 | 1,004,808 | 0.04 | 0.99% |
| 1 Month | 4.87 | 5.00 | 3.92 | 4.32 | 1,290,659 | -0.77 | -15.81% |
| 3 Months | 4.08 | 5.51 | 3.45 | 4.38 | 1,155,824 | 0.02 | 0.49% |
| 6 Months | 4.90 | 5.56 | 3.45 | 4.55 | 1,276,359 | -0.80 | -16.33% |
| 1 Year | 3.15 | 5.79 | 2.40 | 4.33 | 1,897,037 | 0.95 | 30.16% |
| 3 Years | 17.00 | 24.48 | 2.27 | 7.66 | 1,534,713 | -12.90 | -75.88% |
| 5 Years | 17.00 | 24.48 | 2.27 | 7.66 | 1,534,713 | -12.90 | -75.88% |
Amneal Pharmaceuticals Description
| Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment. |
